	US 12,442,823 B2
	Method and reagents for diagnosing membranous nephropathy
Inga-Madeleine Dettmann, Ahrensboek (DE); Swantje Mindorf, Ziethen (DE); and Christian Probst, Ratzeburg (DE)
Assigned to EUROIMMUN Medizinische Labordiagnostika AG, Luebeck (DE)
Filed by EUROIMMUN Medizinische Labordiagnostika AG, Luebeck (DE)
Filed on Dec. 2, 2021, as Appl. No. 17/457,279.
Claims priority of application No. 20213450 (EP), filed on Dec. 11, 2020.
Prior Publication US 2022/0187320 A1, Jun. 16, 2022 Prior Publication US 2023/0213534 A9, Jul. 6, 2023
Int. Cl. G01N 33/68 (2006.01); G01N 33/564 (2006.01)

CPC G01N 33/6893 (2013.01) [G01N 33/564 (2013.01); G01N 33/6857 (2013.01); G01N 2800/347 (2013.01)]

14 Claims

1. A method for detecting an autoantibody to EXT2 or to a complex of EXT2 and EXT1 from a subject having or suspected of having membranous nephropathy, comprising:

detecting the presence of an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1 or to a complex comprising a polypeptide having SEQ ID NO: 1 and a polypeptide having SEQ ID NO: 2 or a variant thereof, in a liquid sample comprising antibodies from a subject having or suspected of having membranous nephropathy.